Cidara Therapeutics (CDTX) AI Stock Analysis

• Market Cap: $2.67B
• Dividend Yield: N/A
• Average Volume (3M): 1.15M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.40
• Revenue Growth: -100.00%
• EPS Growth: 55.31%
• Country: US
• Employees: 38
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.65
• Shares Outstanding: 25,358,051
• 10 Day Avg. Volume: 759,664
• 30 Day Avg. Volume: 1,146,711
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.09
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -2.67
• Enterprise Value/Ebitda: -1.96
• 1Y Price Target: $164.50
• Price Target Upside: 64.53% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 55 Neutral
• Price Target: $102.00 ▲(2.02% Upside)

Cidara Therapeutics' overall score is primarily impacted by its challenging financial performance, with persistent losses and reliance on external financing. However, the positive earnings call, highlighting successful clinical trials and strong financial backing, provides a significant boost. The technical analysis suggests a bullish trend, but the valuation remains a concern due to the negative P/E ratio and non-revenue generating status.

Positive Factors

Regulatory Advancements

The Breakthrough Therapy designation for CD388 by the FDA signifies potential for accelerated development and review, enhancing CDTX's competitive position in the influenza prevention market.

Strong Financial Backing

The substantial financial backing provides Cidara with the necessary resources to advance its clinical trials and development programs, supporting long-term growth and innovation.

Strategic Partnerships

The BARDA award supports CD388's development and manufacturing, indicating strong government partnership and potential for expanded market reach, enhancing CDTX's strategic position.

Negative Factors

Non-Revenue Generating Status

The lack of revenue generation poses financial risks, as the company remains reliant on external funding, impacting its ability to achieve sustainable profitability in the near term.

Negative Cash Flow

Persistent negative cash flow indicates operational inefficiencies and a heavy reliance on external financing, challenging the company's long-term financial sustainability.

Potential Delays in Phase III Study

Delays in the Phase III study could postpone product commercialization, affecting revenue timelines and investor confidence in the company's growth prospects.

Cidara Therapeutics Business Overview & Revenue Model

Company Description

Cidara Therapeutics (CDTX) is a biotechnology company focused on the development of novel therapeutics for the treatment of fungal infections and other serious diseases. The company operates primarily in the biotechnology sector, leveraging its innovative platform to design and develop new medicines that address unmet medical needs. Cidara's core products include its lead candidate, rezafungin, an antifungal agent aimed at treating invasive fungal infections, and its Cloudbreak platform, which is designed for the development of combination therapies.

How the Company Makes Money

Cidara Therapeutics generates revenue primarily through the development and commercialization of its drug candidates. The company likely makes money through milestone payments from partnerships with larger pharmaceutical companies, licensing agreements, and potential royalties from product sales once their therapies are approved and marketed. Significant partnerships with established pharmaceutical firms for co-development or distribution of its products can also contribute to revenue, along with government grants and funding aimed at supporting research and development efforts.

Cidara Therapeutics Financial Statement Overview

Summary

Cidara Therapeutics faces significant financial challenges with persistent losses and negative cash flows. The company has a deeply negative net profit margin and relies heavily on external financing to sustain operations. Despite a low debt-to-equity ratio, the financial trajectory suggests a need for strategic improvements.

Income Statement

Cidara Therapeutics has experienced a significant revenue decline in the latest year, with a revenue growth rate of -98% from the previous year. The net profit margin is deeply negative, at -13362.04% for 2024, indicating substantial losses relative to revenue. The gross profit margin is also negative, suggesting that the company is selling below cost. While biotechnology companies often face high R&D expenses, the magnitude of losses is concerning.

Balance Sheet

The company's debt-to-equity ratio is low due to a relatively high stockholders' equity, indicating low leverage. However, the equity ratio is 76.02%, reflecting a stable capital structure. Despite this, the company has historically negative equity, raising concerns about sustainable financial health. The increase in cash reserves provides some liquidity cushion.

Cash Flow

Operating cash flow is significantly negative, although there has been substantial cash inflow from financing activities. Free cash flow remains negative, and the operating cash flow to net income ratio is negative, due to both operating cash flow and net income being negative. The company is heavily dependent on external financing to sustain operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	1.27M	63.91M	64.29M	49.57M	12.07M
Gross Profit	-90.78M	-83.61M	62.38M	64.14M	49.38M	-55.95M
EBITDA	-124.06M	-176.10M	-24.36M	-33.36M	-42.26M	-71.56M
Net Income	-91.32M	-169.83M	-22.93M	-33.58M	-42.47M	-72.37M
Balance Sheet
Total Assets	534.33M	214.80M	67.03M	47.59M	75.33M	60.42M
Cash, Cash Equivalents and Short-Term Investments	510.57M	189.82M	35.78M	32.73M	62.27M	35.91M
Total Debt	2.33M	3.58M	4.88M	1.21M	5.06M	7.96M
Total Liabilities	33.15M	51.49M	75.24M	50.50M	53.75M	49.71M
Stockholders Equity	501.17M	163.31M	-8.21M	-2.90M	21.57M	10.71M
Cash Flow
Free Cash Flow	-129.13M	-176.66M	-22.94M	-28.59M	-25.27M	-54.60M
Operating Cash Flow	-129.02M	-176.53M	-22.43M	-28.47M	-25.23M	-54.41M
Investing Cash Flow	79.00K	-129.00K	-505.00K	-118.00K	-41.00K	-186.00K
Financing Cash Flow	481.49M	337.06M	25.98M	-951.00K	44.60M	37.28M

Cidara Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 99.98
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CDTX, the sentiment is Positive. The current price of 99.98 is below the 20-day moving average (MA) of 102.56, above the 50-day MA of 83.07, and above the 200-day MA of 44.01, indicating a bullish trend. The MACD of 4.59 indicates Positive momentum. The RSI at 59.62 is Neutral, neither overbought nor oversold. The STOCH value of 37.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CDTX.

Cidara Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CPRX	―	$2.61B	12.96	28.49%	―	28.55%	196.96%
TARS	―	$2.79B	―	-31.46%	―	254.45%	48.06%
IDYA	―	$2.56B	―	-35.09%	―	-41.48%	-73.55%
CDTX	―	$2.67B	-9.44	-37.05%	―	-100.00%	55.31%
ARQT	―	$2.41B	―	-57.33%	―	99.50%	65.91%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BEAM	―	$2.83B	―	-41.94%	―	-82.90%	-155.64%

Cidara Therapeutics Corporate Events

Cidara Therapeutics’ CD388 Study: A Potential Game-Changer in Influenza Prevention

Study Overview: Cidara Therapeutics Inc. is conducting a Phase 3 study titled A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CD388, a Novel Long-Acting Antiviral Conjugate, for the Prevention of Influenza in Adults and Adolescents at Higher Risk of Developing Influenza Complications. The study aims to assess the effectiveness of CD388 in preventing laboratory-confirmed influenza infections and its safety compared to a placebo.

Cidara Therapeutics Expands Phase 3 Trial for CD388

On September 24, 2025, Cidara Therapeutics announced an update to its Phase 3 trial plan for CD388 following discussions with the FDA. The trial will now include a broader population, potentially increasing eligible patients in the U.S. from 50 million to over 100 million, and will begin enrollment by the end of September 2025, six months earlier than initially planned.

The most recent analyst rating on (CDTX) stock is a Buy with a $123.00 price target. To see the full list of analyst forecasts on Cidara Therapeutics stock, see the CDTX Stock Forecast page.

Cidara Therapeutics: Promising Trials Amidst Financial Challenges

Cidara Therapeutics Inc. recently held an earnings call that conveyed a mixed sentiment. On the positive side, the company reported significant progress in its clinical trials and financial positioning, highlighted by robust Phase IIb results and substantial financing. However, challenges such as the absence of revenue generation and potential impacts on study timelines due to lower attack rates in Phase III were also discussed, presenting some concerns.

Cidara Therapeutics Reports Positive Trial Results and Financial Growth

Cidara Therapeutics, Inc. is a biotechnology company based in San Diego, California, specializing in the development of drug-Fc conjugate (DFC) therapeutics using its proprietary Cloudbreak platform. The company focuses on creating innovative treatments for infectious diseases and oncology.